{"version":"1.0","type":"link","title":"Real-world progression-free survival and overall survival in patients with HR/HER2 advanced breast cancer treated in first-line with ribociclib, endocrine monotherapy or chemotherapy: Results from the observational RIBANNA study.","author_name":"Fasching PA 외","author_url":"https://prs-insight.online/author/Fasching%20PA","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/81848","thumbnail_width":1200,"thumbnail_height":630}